Carisma Therapeutics, Inc.
CARM
$0.235
$0.00924.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 2.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 2.08% | |||
| Cost of Revenue | -73.53% | -41.22% | |||
| Gross Profit | 55.33% | 54.49% | |||
| SG&A Expenses | -14.15% | -0.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -55.77% | -33.04% | |||
| Operating Income | 38.10% | 41.13% | |||
| Income Before Tax | -5.48% | 47.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.48% | 47.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.48% | 47.46% | |||
| EBIT | 38.10% | 41.13% | |||
| EBITDA | 33.38% | 42.89% | |||
| EPS Basic | -5.46% | 47.49% | |||
| Normalized Basic EPS | 42.71% | 40.77% | |||
| EPS Diluted | -5.46% | 47.49% | |||
| Normalized Diluted EPS | 42.71% | 40.77% | |||
| Average Basic Shares Outstanding | 0.04% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.04% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||